AR117861A1 - Métodos de reducción de eventos cerebrovasculares en pacientes con enfermedad de fabry - Google Patents
Métodos de reducción de eventos cerebrovasculares en pacientes con enfermedad de fabryInfo
- Publication number
- AR117861A1 AR117861A1 ARP200100155A ARP200100155A AR117861A1 AR 117861 A1 AR117861 A1 AR 117861A1 AR P200100155 A ARP200100155 A AR P200100155A AR P200100155 A ARP200100155 A AR P200100155A AR 117861 A1 AR117861 A1 AR 117861A1
- Authority
- AR
- Argentina
- Prior art keywords
- fabry
- patients
- disease
- reduction methods
- cerebrovascular event
- Prior art date
Links
- 230000007213 cerebrovascular event Effects 0.000 title abstract 4
- 208000024720 Fabry Disease Diseases 0.000 title abstract 3
- 239000012458 free base Substances 0.000 abstract 1
- LXBIFEVIBLOUGU-DPYQTVNSSA-N migalastat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O LXBIFEVIBLOUGU-DPYQTVNSSA-N 0.000 abstract 1
- 229950007469 migalastat Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962795524P | 2019-01-22 | 2019-01-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR117861A1 true AR117861A1 (es) | 2021-09-01 |
Family
ID=69726736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200100155A AR117861A1 (es) | 2019-01-22 | 2020-01-22 | Métodos de reducción de eventos cerebrovasculares en pacientes con enfermedad de fabry |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20220087993A1 (enExample) |
| EP (2) | EP4523750A3 (enExample) |
| JP (2) | JP7680356B2 (enExample) |
| AR (1) | AR117861A1 (enExample) |
| DK (1) | DK3914247T3 (enExample) |
| ES (1) | ES3007212T3 (enExample) |
| FI (1) | FI3914247T3 (enExample) |
| HR (1) | HRP20250078T1 (enExample) |
| HU (1) | HUE069934T2 (enExample) |
| LT (1) | LT3914247T (enExample) |
| PL (1) | PL3914247T3 (enExample) |
| PT (1) | PT3914247T (enExample) |
| RS (1) | RS66410B1 (enExample) |
| SI (1) | SI3914247T1 (enExample) |
| SM (1) | SMT202500034T1 (enExample) |
| TW (1) | TW202042812A (enExample) |
| WO (1) | WO2020154354A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3840753T (lt) * | 2018-08-20 | 2024-11-11 | Amicus Therapeutics, Inc. | Migalastatas skirtas naudoti fabry ligos gydymo būdui, pacientams turintiems gla geno mutaciją |
| KR20220044560A (ko) | 2019-08-07 | 2022-04-08 | 아미쿠스 세라퓨틱스, 인코포레이티드 | Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| EP2142197A4 (en) | 2007-03-30 | 2010-11-10 | Amicus Therapeutics Inc | METHOD FOR THE TREATMENT OF MORBUS FABRY WITH PHARMACOLOGICAL CHAPTERONES |
| US9999618B2 (en) * | 2007-04-26 | 2018-06-19 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
| WO2009102895A2 (en) | 2008-02-12 | 2009-08-20 | Amicus Therapeutics, Inc. | Method to predict response to pharmacological chaperone treatment of diseases |
| WO2018017721A1 (en) * | 2016-07-19 | 2018-01-25 | Amicus Therapeutics, Inc. | Treatment of fabry disease in ert-naïve and ert-experienced patients |
-
2020
- 2020-01-20 TW TW109101869A patent/TW202042812A/zh unknown
- 2020-01-22 FI FIEP20708283.5T patent/FI3914247T3/fi active
- 2020-01-22 LT LTEPPCT/US2020/014531T patent/LT3914247T/lt unknown
- 2020-01-22 AR ARP200100155A patent/AR117861A1/es unknown
- 2020-01-22 HR HRP20250078TT patent/HRP20250078T1/hr unknown
- 2020-01-22 PL PL20708283.5T patent/PL3914247T3/pl unknown
- 2020-01-22 ES ES20708283T patent/ES3007212T3/es active Active
- 2020-01-22 EP EP24212005.3A patent/EP4523750A3/en active Pending
- 2020-01-22 RS RS20250066A patent/RS66410B1/sr unknown
- 2020-01-22 US US17/424,979 patent/US20220087993A1/en active Pending
- 2020-01-22 DK DK20708283.5T patent/DK3914247T3/da active
- 2020-01-22 WO PCT/US2020/014531 patent/WO2020154354A1/en not_active Ceased
- 2020-01-22 SI SI202030569T patent/SI3914247T1/sl unknown
- 2020-01-22 HU HUE20708283A patent/HUE069934T2/hu unknown
- 2020-01-22 EP EP20708283.5A patent/EP3914247B1/en active Active
- 2020-01-22 SM SM20250034T patent/SMT202500034T1/it unknown
- 2020-01-22 JP JP2021542102A patent/JP7680356B2/ja active Active
- 2020-01-22 PT PT207082835T patent/PT3914247T/pt unknown
-
2025
- 2025-05-08 JP JP2025077689A patent/JP2025128105A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| HUE069934T2 (hu) | 2025-04-28 |
| ES3007212T3 (en) | 2025-03-19 |
| LT3914247T (lt) | 2025-01-27 |
| EP3914247A1 (en) | 2021-12-01 |
| EP4523750A2 (en) | 2025-03-19 |
| PT3914247T (pt) | 2025-01-23 |
| JP2022518733A (ja) | 2022-03-16 |
| FI3914247T3 (fi) | 2025-02-16 |
| RS66410B1 (sr) | 2025-02-28 |
| US20220087993A1 (en) | 2022-03-24 |
| WO2020154354A1 (en) | 2020-07-30 |
| PL3914247T3 (pl) | 2025-04-14 |
| EP4523750A3 (en) | 2025-06-11 |
| SI3914247T1 (sl) | 2025-03-31 |
| JP2025128105A (ja) | 2025-09-02 |
| HRP20250078T1 (hr) | 2025-03-28 |
| EP3914247B1 (en) | 2024-11-13 |
| JP7680356B2 (ja) | 2025-05-20 |
| SMT202500034T1 (it) | 2025-03-12 |
| DK3914247T3 (da) | 2025-01-27 |
| TW202042812A (zh) | 2020-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018001677A1 (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert | |
| CL2020000491A1 (es) | Métodos para aumentar y/o estabilizar la función cardiaca en pacientes con enfermedad de fabry. | |
| CL2019003496A1 (es) | Métodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal. | |
| MX2021015338A (es) | Composicion que comprende pridopidina y un analogo de la misma para el tratamiento de la enfermedad de huntington y sintomas de la misma. | |
| MX2025001920A (es) | Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina | |
| MX2020006284A (es) | Tetratiomolibdato de bis-colina para tratar la enfermedad de wilson. | |
| AR114392A1 (es) | Tratamiento de pacientes con enfermedad de fabry clásica | |
| CL2021003280A1 (es) | Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal | |
| MX361741B (es) | Tratamientos médicos a base de anamorelina. | |
| CO2022005113A2 (es) | Métodos de tratamiento para modificar la hemodinámica | |
| EA202090242A1 (ru) | Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов | |
| CL2023000296A1 (es) | Uso de dexpramipexol para el tratamiento del asma moderado a grave | |
| WO2019010301A8 (en) | Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap) | |
| MX2021009384A (es) | Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico. | |
| BR112022008095A2 (pt) | Métodos e composições para o tratamento da síndrome de rett | |
| PE20031047A1 (es) | Tratamiento de padecimientos post-menopausicos en pacientes con cancer de mama | |
| WO2018044132A3 (ko) | 발기부전 환자를 위한 콘돔 | |
| EP4523750A3 (en) | Methods of reducing cerebrovascular events in patients with fabry disease | |
| JOP20200046A1 (ar) | طرق لعلاج أمراض مرتبطة بـtnf? | |
| MX2023003258A (es) | Tratamiento de enfermedades mediadas por nf-kb. | |
| CL2021000444A1 (es) | Métodos para reducir el riesgo de diabetes en pacientes tratados por enfermedades relacionadas con el colesterol alto. | |
| PT1408977E (pt) | Terapia de combinacao para o tratamento de falha cardiaca | |
| AU2020360413A8 (en) | Methods of treating conditions related to the S1P1 receptor | |
| MX2020007627A (es) | Uso de la carrimicina o de sus ingredientes activos. | |
| AR111971A1 (es) | Métodos para tratar pacientes con enfermedad de fabry que tienen insuficiencia renal |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |